Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Shwachman-Diamond Syndrome 1Primary Immunodeficiency Diseases 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia, Severe Congenital, Autosomal Recessive 3 1Myelodysplastic Syndromes 1Melanoma 1Macrophage Activation Syndrome 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Histiocytosis, Langerhans-Cell 1Histiocytosis 1Hemoglobinopathies 1Drug-Related Side Effects and Adverse Reactions 1Colitis 1Bone Marrow Failure Disorders 1Anemia, Sickle Cell 1Anemia, Diamond-Blackfan 1Anemia, Aplastic 1Acquired Immunodeficiency Syndrome 1

Interventions

Social Determinants of Health 2Prednisone 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Drug-Related Side Effects and Adverse Reactions × Methylprednisolone Hemisuccinate × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡